Skip to content
Subscriber Only
Business

Allergan Loses Appeal Over Validity of Restasis Patents

  • Teva, Mylan win ruling that eye drug patents are invalid
  • Appeals court rules a week after hearing arguments on the case
Allergan Plc Offices Ahead Of Earnings Figure

Photographer: Scott Eisen/Bloomberg

By

Allergan Plc’s patents on its blockbuster eye drug Restasis are invalid, a U.S. appeals court ruled Tuesday.

Without issuing a formal opinion, the U.S. Court of Appeals for the Federal Circuit in Washington affirmed a trial court decision that the patents are invalid, in a victory for Teva Pharmaceutical Industries Ltd., Akorn Inc. and Mylan NV. The court ruling came a week after it heard arguments on the case.